Work

Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1

Year: 2012

Type: article

Abstract: Despite multiple studies demonstrating the importance of the anti-apoptotic protein Mcl-1 in tumor cell survival and treatment resistance, a clinically important inhibitor has yet to be developed. A recent study by Guo Wei and colleagues published in Cancer Cell has utilized a novel high-throughput approach to identify compounds that act as transcriptional repressors of MCL1 expression. Their findings identified a number of candidate drugs to be tested for clinical relevance in human cancers dependent on MCL1 expression.

Source: Genome Medicine

DOI: 10.1186/gm352

Authors: Lukas W Pfannenstiel, Abeba Demelash, Brian R Gastman

Institutions: Cleveland Clinic, Cleveland Clinic Research

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,290